NEW YORK (GenomeWeb News) — Shares in Stratagene were down 8.6 percent, or $.59, at $6.24 in mid-afternoon trading today after a judge ordered the company to pay $16 million in damages to Invitrogen for willfully infringing one of its patents.
Separately today, investment bank Robert W. Baird downgraded Stratagene’s stock to ‘Underperform’ from ‘Neutral.’

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.